A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

Clinical trial NCT05060016 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05060016
Sponsor: Amgen
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Relapsed/Refractory Small Cell Lung Cancer

Start date: 2021-12-01
Primary completion: 2027-12-30
Enrollment: 222

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.